References
- Global regulatory workshop on COVID-19 Vaccine development. [Cited 2020 Mar 25. http://www.icmra.info/drupal/sites/default/files/2020-03/First%20regulatory%20COVID-19%20workshop%20-%20meeting%20report_March%202020.pdf
- Wang Q, Zhang L, Kuwahara K, et al., Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2(5): 361–376. 2016.
- Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015;13:123–129.
- Tian X, Li C, Huang A, et al., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 9(1): 382–385. 2020.
- Fischer R, Buyel JF. Molecular farming - The slope of enlightenment. Biotechnol Adv. 2020;40:107519.
- Gleba Y, Klimyuk V, Marillonnet S. Magnifection–a new platform for expressing recombinant vaccines in plants. Vaccine. 2005;23(17–18):2042–2048.
- Klimyuk V, Pogue G, Herz S, et al. Production of recombinant antigens and antibodies in Nicotiana benthamiana using ‘magnifection’ technology: GMP-compliant facilities for small- and large-scale manufacturing. Curr Top Microbiol Immunol. 2014;375:127–154.
- Marsian J, Fox H, Bahar MW, et al. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine. Nat Commun. 2017;8(1):245.
- Choi YS, Moon JH, Kim TG, et al. Potent In Vitro and In Vivo activity of plantibody specific for porphyromonas gingivalis FimA. Clin Vaccine Immunol. 2016;23(4):346–352.
- Mor TS. Molecular pharming’s foot in the FDA’s door: protalix’s trailblazing story. Biotechnol Lett. 2015;37(11):2147–2150.
- Buyel JF, Fischer R. Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs. Biotechnol Bioeng. 2012;109:2575–2588.
- Buyel JF, Woo JA, Cramer SM, et al. The use of quantitative structure–activity relationship models to develop optimized processes for the removal of tobacco host cell proteins during biopharmaceutical production. J Chromatog A. 2013;1322:18–28.
- Pillet S, Couillard J, Trépanier S, et al., Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-two randomized phase II clinical trials in 18 to 49 and ≥50 years old adults. PLoS One. 14(6): e0216533. 2019.
- Tully CM, Lambe T, Gilbert SC, et al. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet Infect Dis. 2015;15:356–359.
- New antibodies best ZMapp in Ebola trial. Nat Biotechnol. 2019;37:1105. https://doi.org/10.1038/s41587-019-0284-y
- Stelter S, Paul MJ, Teh AY, et al. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. Plant Biotechnol J. 2020;18(2):402–414.
- Phoolcharoen W, Banyard AC, Prehaud C, et al. In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity. Vaccine. 2019;37(33):4673–4680.
- LÉC M, Silva BB, Dutra RF, et al. Transient expression of dengue virus NS1 antigen in Nicotiana benthamiana for use as a diagnostic antigen. Front Plant Sci. 2020;10:1674.
- Rybicki EP. Plant molecular farming of virus-like nanoparticles as vaccines and reagents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(2):e1587.
- Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine. 2016;34(4):413–423.
- CBER Advanced Technologies Program. [Cited 2020 Mar 25]. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/cber-advanced-technologies-program